GlassScriptPhysician profile
Nhu Thinh Vo
NPI 1588291140
$1,598.67
in general payments reported to CMS, 2019-2025
22 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.94 · 2023: $177 · 2024: $776 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $412.83 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $213.28 | 2023-2025 | |
| Astellas Pharma US INC | $163.70 | 2023-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $125.24 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $94.45 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $89.61 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $75.27 | 2024-2025 | Xyosted |
| Lilly USA, LLC | $72.42 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $59.09 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $53.86 | 2024-2025 | |
| Glaxosmithkline, LLC. | $28.48 | 2023-2024 | Shingrix, Bexsero, Arexvy |
| Corcept Therapeutics | $26.79 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $22.98 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $20.77 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $20.75 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $19.59 | 2024 | Unithroid |
| Organon LLC | $18.72 | 2024 | |
| Abbvie INC. | $18.53 | 2025 | |
| Dexcom, INC. | $17.52 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $16.55 | 2024 | Otezla, Repatha |
| Halozyme INC | $14.25 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.99 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhu Thinh Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.